A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive,HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)
研究单位：[1]Hoffmann-La Roche[2]Department of Breast Chengdu,China,610041[3]Departamento de Ginecologia E Mama Goiania,GO,Brazil,74605-070[4]Sichuan Cancer Hospital Chengdu City,China,610041[5]West China Hospital,Sichuan University[6]Fujian Medical University Union Hospital Fuzhou City,China,350001[7]Tom Baker Cancer Centre-Calgary Calgary,Alberta,Canada,T2N 4N2[8]Hospital Sao Rafael - HSR Salvador,BA,Brazil,41253-190[9]Hospital Araujo Jorge[10]Hospital do Cancer de Pernambuco - HCP Recife,PE,Brazil,50040-000[11]Santa Casa de Misericordia de Porto Alegre Porto Alegre,RS,Brazil,90050-170[12]Hospital Sao Lucas - PUCRS Porto Alegre,RS,Brazil,90610-000[13]Hospital de Base de Sao Jose do Rio Preto Sao Jose do Rio Preto,SP,Brazil,15090-000
研究目的：
This Phase III,randomized,double-blind,placebo-controlled,multicenter study will evaluate the efficacy and safety of giredestrant combined with palbociclib compared with letrozole combined with palbociclib in patients with estrogen receptor (ER)-positive,human epidermal growth factor receptor-2 (HER2)-negative locally advanced (recurrent or progressed) or metastatic breast cancer.
